| A single administration of bimatoprost sustained-release implant (Bimatoprost SR) lowered intraocular pressure for up to 1 year in 40% of patients and up to 2 years in 28%, with no additional treatment. |
| Efficacy of re-administration with a second implant of Bimatoprost SR was similar to that with the first implant. |
| The safety profile of Bimatoprost SR was favorable during the 24-month study. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.